RxDoctor Payments Data

Cristina Cusin, MD

Psychiatry · Boston, MANPI 1003942426

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Livanova USA, Inc. at 47.3% of the total. Reporting peaked in 2024 at $7,276 and has fallen 64.6% since, to $2,574 in 2025. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,123in general payments, 2019–2025

Across 34 payments — averaging $503.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$8K
  • Johnson & Johnson$6K
  • Boehringer Ingelheim$3K
  • Abbott$336
  • Janssen Scientific Affairs, LLC$74
  • Biogen$49
$312,834in research payments, 2019–2025

Across 185 payments — averaging $1690.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Livanova USA, Inc.$292K
  • Janssen Research & Development, LLC$21K

What the payments were for

  • Consulting fees$7,27542%
  • Speaking & faculty fees$5,20030%
  • Travel & lodging$3,62721%
  • Food & beverage$1,0226%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,123 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$86,689
Medicare patients
63
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$108,736
TrintellixVortioxetine Hydrobromide26$24,965
Effexor XrVenlafaxine Hcl13$18,499
Methylphenidate ErMethylphenidate Hcl30$1,346
Bupropion XlBupropion Hcl25$1,016
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$732
Lamotrigine21$574
Clonazepam52$573
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine33$510
Methylphenidate Hcl29$464
Duloxetine Hcl18$445
Clozapine21$375
Bupropion Hcl19$309
Mirtazapine11$299
Quetiapine Fumarate19$221

Paid to pharmacies, not to this prescriber.

Other psychiatry in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →